Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

Showing products 1–24 of 87. More products

SITAGLIPTIN

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (A10B, A10BH) — coverage varies; not interchangeable

  • Linagliptin (Trajenta): general benefit
  • Saxagliptin (Onglyza): general benefit
  • Canagliflozin (Invokana): general benefit
  • Dapagliflozin (Forxiga): general benefit
  • Dapagliflozin + metformin (Xigduo): general benefit
  • Empagliflozin (Jardiance): general benefit

11 more in the class list below

Ach-Sitagliptin · DIN 02512475 · 25mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Ach-Sitagliptin · DIN 02512475 Manufacturer: Accord Healthcare Inc.; listing date 2023-07-31 Health Canada: Marketed since 2023-05-12 · brand ACH-SITAGLIPTIN · ATC A10BH01 SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE) 25 MG · company Accord healthcare inc · schedule Prescription
Check this DIN again · Health Canada product record

Ach-Sitagliptin: Formulary list price $0.8197/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.8197 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100176 · Verify on the e-Formulary ↗ (DIN 02512475)

Source record
DIN 02512475: Ach-Sitagliptin Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002046; group id 756; item number 1854; lccId None; manufacturer id ACH Source form: Tab; strength: 25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.8197; ministry $0.8197 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02512475 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100176 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Sitagliptin · DIN 02428261 · $0.8197 Apo-Sitagliptin Malate · DIN 02508656 · $0.8197 Auro-Sitagliptin · DIN 02529866 · $0.8197 Jamp Sitagliptin · DIN 02534134 · $0.8197 Januvia · DIN 02388839 · $0.8197 M-Sitagliptin · DIN 02534983 · $0.8197 Mint-Sitagliptin · DIN 02553910 · $0.8197 NAT-Sitagliptin · DIN 02558157 · $0.8197 PMS-Sitagliptin · DIN 02503840 · $0.8197 PRZ-Sitagliptin · DIN 02545837 · $0.8197 Sandoz Sitagliptin · DIN 02504049 · $0.8197 Sitagliptin · DIN 02529033 · $0.8197 Sitagliptin · DIN 02548550 · $0.8197 Taro-Sitagliptin Fumarate · DIN 02531631 · $0.8197 Teva-Sitagliptin Malate · DIN 02522705 · $0.8197
Shortage status: active shortage (reported 2024-06-28, last updated 2024-08-09) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02512475
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Sitagliptin · DIN 02428261 · 25mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Sitagliptin · DIN 02428261 Manufacturer: Apotex Inc.; listing date 2026-01-30 Health Canada: Marketed since 2025-12-22 · brand APO-SITAGLIPTIN · ATC A10BH01 SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 25 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Sitagliptin: Formulary list price $0.8197/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.8197 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91274 · Verify on the e-Formulary ↗ (DIN 02428261)

Source record
DIN 02428261: Apo-Sitagliptin Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002046; group id 756; item number 1854; lccId None; manufacturer id APX Source form: Tab; strength: 25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.8197; ministry $0.8197 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02428261 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91274 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Ach-Sitagliptin · DIN 02512475 · $0.8197 Apo-Sitagliptin Malate · DIN 02508656 · $0.8197 Auro-Sitagliptin · DIN 02529866 · $0.8197 Jamp Sitagliptin · DIN 02534134 · $0.8197 Januvia · DIN 02388839 · $0.8197 M-Sitagliptin · DIN 02534983 · $0.8197 Mint-Sitagliptin · DIN 02553910 · $0.8197 NAT-Sitagliptin · DIN 02558157 · $0.8197 PMS-Sitagliptin · DIN 02503840 · $0.8197 PRZ-Sitagliptin · DIN 02545837 · $0.8197 Sandoz Sitagliptin · DIN 02504049 · $0.8197 Sitagliptin · DIN 02529033 · $0.8197 Sitagliptin · DIN 02548550 · $0.8197 Taro-Sitagliptin Fumarate · DIN 02531631 · $0.8197 Teva-Sitagliptin Malate · DIN 02522705 · $0.8197
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02428261
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Sitagliptin Malate · DIN 02508656 · 25mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Sitagliptin Malate · DIN 02508656 Manufacturer: Apotex Inc.; listing date 2022-12-21 Health Canada: Marketed since 2022-11-07 · brand APO-SITAGLIPTIN MALATE · ATC A10BH01 SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN MALATE) 25 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Sitagliptin Malate: Formulary list price $0.8197/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.8197 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99800 · Verify on the e-Formulary ↗ (DIN 02508656)

Source record
DIN 02508656: Apo-Sitagliptin Malate Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002046; group id 756; item number 1854; lccId None; manufacturer id APX Source form: Tab; strength: 25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.8197; ministry $0.8197 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02508656 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99800 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Ach-Sitagliptin · DIN 02512475 · $0.8197 Apo-Sitagliptin · DIN 02428261 · $0.8197 Auro-Sitagliptin · DIN 02529866 · $0.8197 Jamp Sitagliptin · DIN 02534134 · $0.8197 Januvia · DIN 02388839 · $0.8197 M-Sitagliptin · DIN 02534983 · $0.8197 Mint-Sitagliptin · DIN 02553910 · $0.8197 NAT-Sitagliptin · DIN 02558157 · $0.8197 PMS-Sitagliptin · DIN 02503840 · $0.8197 PRZ-Sitagliptin · DIN 02545837 · $0.8197 Sandoz Sitagliptin · DIN 02504049 · $0.8197 Sitagliptin · DIN 02529033 · $0.8197 Sitagliptin · DIN 02548550 · $0.8197 Taro-Sitagliptin Fumarate · DIN 02531631 · $0.8197 Teva-Sitagliptin Malate · DIN 02522705 · $0.8197
Shortage status: active shortage (reported 2025-10-14, last updated 2026-01-29); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02508656
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Sitagliptin · DIN 02529866 · 25mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Sitagliptin · DIN 02529866 Manufacturer: Auro Pharma Inc.; listing date 2023-03-31 Health Canada: Marketed since 2023-01-05 · brand AURO-SITAGLIPTIN · ATC A10BH01 SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE) 25 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Sitagliptin: Formulary list price $0.8197/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.8197 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101909 · Verify on the e-Formulary ↗ (DIN 02529866)

Source record
DIN 02529866: Auro-Sitagliptin Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002046; group id 756; item number 1854; lccId None; manufacturer id AUR Source form: Tab; strength: 25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.8197; ministry $0.8197 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02529866 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101909 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Ach-Sitagliptin · DIN 02512475 · $0.8197 Apo-Sitagliptin · DIN 02428261 · $0.8197 Apo-Sitagliptin Malate · DIN 02508656 · $0.8197 Jamp Sitagliptin · DIN 02534134 · $0.8197 Januvia · DIN 02388839 · $0.8197 M-Sitagliptin · DIN 02534983 · $0.8197 Mint-Sitagliptin · DIN 02553910 · $0.8197 NAT-Sitagliptin · DIN 02558157 · $0.8197 PMS-Sitagliptin · DIN 02503840 · $0.8197 PRZ-Sitagliptin · DIN 02545837 · $0.8197 Sandoz Sitagliptin · DIN 02504049 · $0.8197 Sitagliptin · DIN 02529033 · $0.8197 Sitagliptin · DIN 02548550 · $0.8197 Taro-Sitagliptin Fumarate · DIN 02531631 · $0.8197 Teva-Sitagliptin Malate · DIN 02522705 · $0.8197
Shortage status: resolved shortage (ended 2025-01-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02529866
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Sitagliptin · DIN 02534134 · 25mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Sitagliptin · DIN 02534134 Manufacturer: Jamp Pharma Corporation; listing date 2023-03-31 Health Canada: Marketed since 2023-02-02 · brand JAMP SITAGLIPTIN · ATC A10BH01 SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE) 25 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Sitagliptin: Formulary list price $0.8197/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.8197 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102308 · Verify on the e-Formulary ↗ (DIN 02534134)

Source record
DIN 02534134: Jamp Sitagliptin Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002046; group id 756; item number 1854; lccId None; manufacturer id JPC Source form: Tab; strength: 25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.8197; ministry $0.8197 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02534134 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102308 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Ach-Sitagliptin · DIN 02512475 · $0.8197 Apo-Sitagliptin · DIN 02428261 · $0.8197 Apo-Sitagliptin Malate · DIN 02508656 · $0.8197 Auro-Sitagliptin · DIN 02529866 · $0.8197 Januvia · DIN 02388839 · $0.8197 M-Sitagliptin · DIN 02534983 · $0.8197 Mint-Sitagliptin · DIN 02553910 · $0.8197 NAT-Sitagliptin · DIN 02558157 · $0.8197 PMS-Sitagliptin · DIN 02503840 · $0.8197 PRZ-Sitagliptin · DIN 02545837 · $0.8197 Sandoz Sitagliptin · DIN 02504049 · $0.8197 Sitagliptin · DIN 02529033 · $0.8197 Sitagliptin · DIN 02548550 · $0.8197 Taro-Sitagliptin Fumarate · DIN 02531631 · $0.8197 Teva-Sitagliptin Malate · DIN 02522705 · $0.8197
Shortage status: resolved shortage (ended 2026-03-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02534134
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Januvia · DIN 02388839 · 25mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Januvia · DIN 02388839 Manufacturer: Merck Frosst Canada Ltd.; listing date 2013-09-27 Health Canada: Marketed since 2012-09-17 · brand JANUVIA · ATC A10BH01 SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 25 MG · company Merck canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.8197 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87438 · Verify on the e-Formulary ↗ (DIN 02388839)

Source record
DIN 02388839: Januvia Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002046; group id 756; item number 1854; lccId None; manufacturer id MFC Source form: Tab; strength: 25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $3.4098; ministry $0.8197 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02388839 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87438 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Ach-Sitagliptin · DIN 02512475 · $0.8197 Apo-Sitagliptin · DIN 02428261 · $0.8197 Apo-Sitagliptin Malate · DIN 02508656 · $0.8197 Auro-Sitagliptin · DIN 02529866 · $0.8197 Jamp Sitagliptin · DIN 02534134 · $0.8197 M-Sitagliptin · DIN 02534983 · $0.8197 Mint-Sitagliptin · DIN 02553910 · $0.8197 NAT-Sitagliptin · DIN 02558157 · $0.8197 PMS-Sitagliptin · DIN 02503840 · $0.8197 PRZ-Sitagliptin · DIN 02545837 · $0.8197 Sandoz Sitagliptin · DIN 02504049 · $0.8197 Sitagliptin · DIN 02529033 · $0.8197 Sitagliptin · DIN 02548550 · $0.8197 Taro-Sitagliptin Fumarate · DIN 02531631 · $0.8197 Teva-Sitagliptin Malate · DIN 02522705 · $0.8197
Shortage status: avoided shortage; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02388839
Shortage record checked 2026-09-13T08:10:21.292534+00:00

M-Sitagliptin · DIN 02534983 · 25mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
M-Sitagliptin · DIN 02534983 Manufacturer: Mantra Pharma Inc.; listing date 2026-07-31 Health Canada: Marketed since 2026-05-11 · brand M-SITAGLIPTIN · ATC A10BH01 SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 25 MG · company Mantra pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

M-Sitagliptin: Formulary list price $0.8197/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.8197 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102387 · Verify on the e-Formulary ↗ (DIN 02534983)

Source record
DIN 02534983: M-Sitagliptin Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002046; group id 756; item number 1854; lccId None; manufacturer id MAT Source form: Tab; strength: 25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.8197; ministry $0.8197 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02534983 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102387 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Ach-Sitagliptin · DIN 02512475 · $0.8197 Apo-Sitagliptin · DIN 02428261 · $0.8197 Apo-Sitagliptin Malate · DIN 02508656 · $0.8197 Auro-Sitagliptin · DIN 02529866 · $0.8197 Jamp Sitagliptin · DIN 02534134 · $0.8197 Januvia · DIN 02388839 · $0.8197 Mint-Sitagliptin · DIN 02553910 · $0.8197 NAT-Sitagliptin · DIN 02558157 · $0.8197 PMS-Sitagliptin · DIN 02503840 · $0.8197 PRZ-Sitagliptin · DIN 02545837 · $0.8197 Sandoz Sitagliptin · DIN 02504049 · $0.8197 Sitagliptin · DIN 02529033 · $0.8197 Sitagliptin · DIN 02548550 · $0.8197 Taro-Sitagliptin Fumarate · DIN 02531631 · $0.8197 Teva-Sitagliptin Malate · DIN 02522705 · $0.8197
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02534983
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mint-Sitagliptin · DIN 02553910 · 25mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mint-Sitagliptin · DIN 02553910 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2026-03-31 Health Canada: Marketed since 2025-12-10 · brand MINT-SITAGLIPTIN · ATC A10BH01 SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE) 25 MG · company Mint pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mint-Sitagliptin: Formulary list price $0.8197/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.8197 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104281 · Verify on the e-Formulary ↗ (DIN 02553910)

Source record
DIN 02553910: Mint-Sitagliptin Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002046; group id 756; item number 1854; lccId None; manufacturer id MIN Source form: Tab; strength: 25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.8197; ministry $0.8197 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02553910 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104281 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Ach-Sitagliptin · DIN 02512475 · $0.8197 Apo-Sitagliptin · DIN 02428261 · $0.8197 Apo-Sitagliptin Malate · DIN 02508656 · $0.8197 Auro-Sitagliptin · DIN 02529866 · $0.8197 Jamp Sitagliptin · DIN 02534134 · $0.8197 Januvia · DIN 02388839 · $0.8197 M-Sitagliptin · DIN 02534983 · $0.8197 NAT-Sitagliptin · DIN 02558157 · $0.8197 PMS-Sitagliptin · DIN 02503840 · $0.8197 PRZ-Sitagliptin · DIN 02545837 · $0.8197 Sandoz Sitagliptin · DIN 02504049 · $0.8197 Sitagliptin · DIN 02529033 · $0.8197 Sitagliptin · DIN 02548550 · $0.8197 Taro-Sitagliptin Fumarate · DIN 02531631 · $0.8197 Teva-Sitagliptin Malate · DIN 02522705 · $0.8197
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02553910
Shortage record checked 2026-09-13T08:10:21.292534+00:00

NAT-Sitagliptin · DIN 02558157 · 25mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
NAT-Sitagliptin · DIN 02558157 Manufacturer: Natco Pharma (Canada) Inc.; listing date 2026-02-27 Health Canada: Marketed since 2026-01-06 · brand NAT-SITAGLIPTIN · ATC A10BH01 SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 25 MG · company Natco pharma (canada) inc · schedule Prescription
Check this DIN again · Health Canada product record

NAT-Sitagliptin: Formulary list price $0.8197/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.8197 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106144 · Verify on the e-Formulary ↗ (DIN 02558157)

Source record
DIN 02558157: NAT-Sitagliptin Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002046; group id 756; item number 1854; lccId None; manufacturer id NAT Source form: Tab; strength: 25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.8197; ministry $0.8197 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02558157 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106144 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Ach-Sitagliptin · DIN 02512475 · $0.8197 Apo-Sitagliptin · DIN 02428261 · $0.8197 Apo-Sitagliptin Malate · DIN 02508656 · $0.8197 Auro-Sitagliptin · DIN 02529866 · $0.8197 Jamp Sitagliptin · DIN 02534134 · $0.8197 Januvia · DIN 02388839 · $0.8197 M-Sitagliptin · DIN 02534983 · $0.8197 Mint-Sitagliptin · DIN 02553910 · $0.8197 PMS-Sitagliptin · DIN 02503840 · $0.8197 PRZ-Sitagliptin · DIN 02545837 · $0.8197 Sandoz Sitagliptin · DIN 02504049 · $0.8197 Sitagliptin · DIN 02529033 · $0.8197 Sitagliptin · DIN 02548550 · $0.8197 Taro-Sitagliptin Fumarate · DIN 02531631 · $0.8197 Teva-Sitagliptin Malate · DIN 02522705 · $0.8197
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02558157
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Sitagliptin · DIN 02503840 · 25mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Sitagliptin · DIN 02503840 Manufacturer: Pharmascience Inc.; listing date 2025-01-31 Health Canada: Marketed since 2024-11-26 · brand PMS-SITAGLIPTIN · ATC A10BH01 SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 25 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Sitagliptin: Formulary list price $0.8197/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.8197 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99328 · Verify on the e-Formulary ↗ (DIN 02503840)

Source record
DIN 02503840: PMS-Sitagliptin Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002046; group id 756; item number 1854; lccId None; manufacturer id PMS Source form: Tab; strength: 25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.8197; ministry $0.8197 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02503840 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99328 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Ach-Sitagliptin · DIN 02512475 · $0.8197 Apo-Sitagliptin · DIN 02428261 · $0.8197 Apo-Sitagliptin Malate · DIN 02508656 · $0.8197 Auro-Sitagliptin · DIN 02529866 · $0.8197 Jamp Sitagliptin · DIN 02534134 · $0.8197 Januvia · DIN 02388839 · $0.8197 M-Sitagliptin · DIN 02534983 · $0.8197 Mint-Sitagliptin · DIN 02553910 · $0.8197 NAT-Sitagliptin · DIN 02558157 · $0.8197 PRZ-Sitagliptin · DIN 02545837 · $0.8197 Sandoz Sitagliptin · DIN 02504049 · $0.8197 Sitagliptin · DIN 02529033 · $0.8197 Sitagliptin · DIN 02548550 · $0.8197 Taro-Sitagliptin Fumarate · DIN 02531631 · $0.8197 Teva-Sitagliptin Malate · DIN 02522705 · $0.8197
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02503840
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PRZ-Sitagliptin · DIN 02545837 · 25mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PRZ-Sitagliptin · DIN 02545837 Manufacturer: Pharmaris Canada Inc.; listing date 2026-05-29 Health Canada: Marketed since 2026-02-10 · brand PRZ-SITAGLIPTIN · ATC A10BH01 SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 25 MG · company Pharmaris canada inc · schedule Prescription
Check this DIN again · Health Canada product record

PRZ-Sitagliptin: Formulary list price $0.8197/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.8197 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103457 · Verify on the e-Formulary ↗ (DIN 02545837)

Source record
DIN 02545837: PRZ-Sitagliptin Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002046; group id 756; item number 1854; lccId None; manufacturer id PRZ Source form: Tab; strength: 25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.8197; ministry $0.8197 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02545837 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103457 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Ach-Sitagliptin · DIN 02512475 · $0.8197 Apo-Sitagliptin · DIN 02428261 · $0.8197 Apo-Sitagliptin Malate · DIN 02508656 · $0.8197 Auro-Sitagliptin · DIN 02529866 · $0.8197 Jamp Sitagliptin · DIN 02534134 · $0.8197 Januvia · DIN 02388839 · $0.8197 M-Sitagliptin · DIN 02534983 · $0.8197 Mint-Sitagliptin · DIN 02553910 · $0.8197 NAT-Sitagliptin · DIN 02558157 · $0.8197 PMS-Sitagliptin · DIN 02503840 · $0.8197 Sandoz Sitagliptin · DIN 02504049 · $0.8197 Sitagliptin · DIN 02529033 · $0.8197 Sitagliptin · DIN 02548550 · $0.8197 Taro-Sitagliptin Fumarate · DIN 02531631 · $0.8197 Teva-Sitagliptin Malate · DIN 02522705 · $0.8197
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02545837
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Sitagliptin · DIN 02504049 · 25mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Sitagliptin · DIN 02504049 Manufacturer: Sandoz Canada Inc.; listing date 2023-03-31 Health Canada: Marketed since 2023-01-05 · brand SANDOZ SITAGLIPTIN · ATC A10BH01 SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 25 MG · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Sandoz Sitagliptin: Formulary list price $0.8197/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.8197 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99350 · Verify on the e-Formulary ↗ (DIN 02504049)

Source record
DIN 02504049: Sandoz Sitagliptin Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002046; group id 756; item number 1854; lccId None; manufacturer id SDZ Source form: Tab; strength: 25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.8197; ministry $0.8197 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02504049 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99350 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Ach-Sitagliptin · DIN 02512475 · $0.8197 Apo-Sitagliptin · DIN 02428261 · $0.8197 Apo-Sitagliptin Malate · DIN 02508656 · $0.8197 Auro-Sitagliptin · DIN 02529866 · $0.8197 Jamp Sitagliptin · DIN 02534134 · $0.8197 Januvia · DIN 02388839 · $0.8197 M-Sitagliptin · DIN 02534983 · $0.8197 Mint-Sitagliptin · DIN 02553910 · $0.8197 NAT-Sitagliptin · DIN 02558157 · $0.8197 PMS-Sitagliptin · DIN 02503840 · $0.8197 PRZ-Sitagliptin · DIN 02545837 · $0.8197 Sitagliptin · DIN 02529033 · $0.8197 Sitagliptin · DIN 02548550 · $0.8197 Taro-Sitagliptin Fumarate · DIN 02531631 · $0.8197 Teva-Sitagliptin Malate · DIN 02522705 · $0.8197
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02504049
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sitagliptin · DIN 02529033 · 25mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sitagliptin · DIN 02529033 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2023-04-28 Health Canada: Marketed since 2023-01-26 · brand SITAGLIPTIN · ATC A10BH01 SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 25 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Sitagliptin: Formulary list price $0.8197/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.8197 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101823 · Verify on the e-Formulary ↗ (DIN 02529033)

Source record
DIN 02529033: Sitagliptin Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002046; group id 756; item number 1854; lccId None; manufacturer id SIV Source form: Tab; strength: 25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.8197; ministry $0.8197 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02529033 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101823 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Ach-Sitagliptin · DIN 02512475 · $0.8197 Apo-Sitagliptin · DIN 02428261 · $0.8197 Apo-Sitagliptin Malate · DIN 02508656 · $0.8197 Auro-Sitagliptin · DIN 02529866 · $0.8197 Jamp Sitagliptin · DIN 02534134 · $0.8197 Januvia · DIN 02388839 · $0.8197 M-Sitagliptin · DIN 02534983 · $0.8197 Mint-Sitagliptin · DIN 02553910 · $0.8197 NAT-Sitagliptin · DIN 02558157 · $0.8197 PMS-Sitagliptin · DIN 02503840 · $0.8197 PRZ-Sitagliptin · DIN 02545837 · $0.8197 Sandoz Sitagliptin · DIN 02504049 · $0.8197 Sitagliptin · DIN 02548550 · $0.8197 Taro-Sitagliptin Fumarate · DIN 02531631 · $0.8197 Teva-Sitagliptin Malate · DIN 02522705 · $0.8197
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02529033
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sitagliptin · DIN 02548550 · 25mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sitagliptin · DIN 02548550 Manufacturer: Sanis Health Inc.; listing date 2025-02-28 Health Canada: Marketed since 2024-12-17 · brand SITAGLIPTIN · ATC not recorded · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 25 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Sitagliptin: Formulary list price $0.8197/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.8197 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103741 · Verify on the e-Formulary ↗ (DIN 02548550)

Source record
DIN 02548550: Sitagliptin Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002046; group id 756; item number 1854; lccId None; manufacturer id SAI Source form: Tab; strength: 25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.8197; ministry $0.8197 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02548550 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103741 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Ach-Sitagliptin · DIN 02512475 · $0.8197 Apo-Sitagliptin · DIN 02428261 · $0.8197 Apo-Sitagliptin Malate · DIN 02508656 · $0.8197 Auro-Sitagliptin · DIN 02529866 · $0.8197 Jamp Sitagliptin · DIN 02534134 · $0.8197 Januvia · DIN 02388839 · $0.8197 M-Sitagliptin · DIN 02534983 · $0.8197 Mint-Sitagliptin · DIN 02553910 · $0.8197 NAT-Sitagliptin · DIN 02558157 · $0.8197 PMS-Sitagliptin · DIN 02503840 · $0.8197 PRZ-Sitagliptin · DIN 02545837 · $0.8197 Sandoz Sitagliptin · DIN 02504049 · $0.8197 Sitagliptin · DIN 02529033 · $0.8197 Taro-Sitagliptin Fumarate · DIN 02531631 · $0.8197 Teva-Sitagliptin Malate · DIN 02522705 · $0.8197
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02548550
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Taro-Sitagliptin Fumarate · DIN 02531631 · 25mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Taro-Sitagliptin Fumarate · DIN 02531631 Manufacturer: Taro Pharmaceuticals Inc.; listing date 2023-03-31 Health Canada: Marketed since 2023-01-05 · brand TARO-SITAGLIPTIN FUMARATE · ATC A10BH01 SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN FUMARATE) 25 MG · company Taro pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Taro-Sitagliptin Fumarate: Formulary list price $0.8197/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.8197 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102075 · Verify on the e-Formulary ↗ (DIN 02531631)

Source record
DIN 02531631: Taro-Sitagliptin Fumarate Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002046; group id 756; item number 1854; lccId None; manufacturer id TAR Source form: Tab; strength: 25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.8197; ministry $0.8197 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02531631 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102075 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Ach-Sitagliptin · DIN 02512475 · $0.8197 Apo-Sitagliptin · DIN 02428261 · $0.8197 Apo-Sitagliptin Malate · DIN 02508656 · $0.8197 Auro-Sitagliptin · DIN 02529866 · $0.8197 Jamp Sitagliptin · DIN 02534134 · $0.8197 Januvia · DIN 02388839 · $0.8197 M-Sitagliptin · DIN 02534983 · $0.8197 Mint-Sitagliptin · DIN 02553910 · $0.8197 NAT-Sitagliptin · DIN 02558157 · $0.8197 PMS-Sitagliptin · DIN 02503840 · $0.8197 PRZ-Sitagliptin · DIN 02545837 · $0.8197 Sandoz Sitagliptin · DIN 02504049 · $0.8197 Sitagliptin · DIN 02529033 · $0.8197 Sitagliptin · DIN 02548550 · $0.8197 Teva-Sitagliptin Malate · DIN 02522705 · $0.8197
Shortage status: active shortage (reported 2026-06-01, estimated to end 2026-10-02, last updated 2026-09-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02531631
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Sitagliptin Malate · DIN 02522705 · 25mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Sitagliptin Malate · DIN 02522705 Manufacturer: Teva Canada Limited; listing date 2024-03-28 Health Canada: Marketed since 2023-08-31 · brand TEVA-SITAGLIPTIN MALATE · ATC A10BH01 SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN MALATE) 25 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Sitagliptin Malate: Formulary list price $0.8197/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.8197 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101181 · Verify on the e-Formulary ↗ (DIN 02522705)

Source record
DIN 02522705: Teva-Sitagliptin Malate Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002046; group id 756; item number 1854; lccId None; manufacturer id TEV Source form: Tab; strength: 25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.8197; ministry $0.8197 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02522705 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101181 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Ach-Sitagliptin · DIN 02512475 · $0.8197 Apo-Sitagliptin · DIN 02428261 · $0.8197 Apo-Sitagliptin Malate · DIN 02508656 · $0.8197 Auro-Sitagliptin · DIN 02529866 · $0.8197 Jamp Sitagliptin · DIN 02534134 · $0.8197 Januvia · DIN 02388839 · $0.8197 M-Sitagliptin · DIN 02534983 · $0.8197 Mint-Sitagliptin · DIN 02553910 · $0.8197 NAT-Sitagliptin · DIN 02558157 · $0.8197 PMS-Sitagliptin · DIN 02503840 · $0.8197 PRZ-Sitagliptin · DIN 02545837 · $0.8197 Sandoz Sitagliptin · DIN 02504049 · $0.8197 Sitagliptin · DIN 02529033 · $0.8197 Sitagliptin · DIN 02548550 · $0.8197 Taro-Sitagliptin Fumarate · DIN 02531631 · $0.8197
Shortage status: active shortage (reported 2025-03-05, last updated 2025-12-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02522705
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ach-Sitagliptin · DIN 02512483 · 50mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Ach-Sitagliptin · DIN 02512483 Manufacturer: Accord Healthcare Inc.; listing date 2023-07-31 Health Canada: Marketed since 2023-05-12 · brand ACH-SITAGLIPTIN · ATC A10BH01 SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE) 50 MG · company Accord healthcare inc · schedule Prescription
Check this DIN again · Health Canada product record

Ach-Sitagliptin: Formulary list price $0.8197/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.8197 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100177 · Verify on the e-Formulary ↗ (DIN 02512483)

Source record
DIN 02512483: Ach-Sitagliptin Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002047; group id 756; item number 1855; lccId None; manufacturer id ACH Source form: Tab; strength: 50mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.8197; ministry $0.8197 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02512483 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100177 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Sitagliptin · DIN 02428288 · $0.8197 Apo-Sitagliptin Malate · DIN 02508664 · $0.8197 Auro-Sitagliptin · DIN 02529874 · $0.8197 Jamp Sitagliptin · DIN 02534142 · $0.8197 Januvia · DIN 02388847 · $0.8197 M-Sitagliptin · DIN 02534991 · $0.8197 Mint-Sitagliptin · DIN 02553929 · $0.8197 NAT-Sitagliptin · DIN 02558165 · $0.8197 PMS-Sitagliptin · DIN 02503859 · $0.8197 PRZ-Sitagliptin · DIN 02545845 · $0.8197 Sandoz Sitagliptin · DIN 02504057 · $0.8197 Sitagliptin · DIN 02529041 · $0.8197 Sitagliptin · DIN 02548569 · $0.8197 Taro-Sitagliptin Fumarate · DIN 02531658 · $0.8197 Teva-Sitagliptin Malate · DIN 02522713 · $0.8197
Shortage status: active shortage (reported 2024-06-28, last updated 2024-08-09) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02512483
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Sitagliptin · DIN 02428288 · 50mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Sitagliptin · DIN 02428288 Manufacturer: Apotex Inc.; listing date 2026-01-30 Health Canada: Marketed since 2025-12-22 · brand APO-SITAGLIPTIN · ATC A10BH01 SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Sitagliptin: Formulary list price $0.8197/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.8197 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91275 · Verify on the e-Formulary ↗ (DIN 02428288)

Source record
DIN 02428288: Apo-Sitagliptin Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002047; group id 756; item number 1855; lccId None; manufacturer id APX Source form: Tab; strength: 50mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.8197; ministry $0.8197 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02428288 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91275 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Ach-Sitagliptin · DIN 02512483 · $0.8197 Apo-Sitagliptin Malate · DIN 02508664 · $0.8197 Auro-Sitagliptin · DIN 02529874 · $0.8197 Jamp Sitagliptin · DIN 02534142 · $0.8197 Januvia · DIN 02388847 · $0.8197 M-Sitagliptin · DIN 02534991 · $0.8197 Mint-Sitagliptin · DIN 02553929 · $0.8197 NAT-Sitagliptin · DIN 02558165 · $0.8197 PMS-Sitagliptin · DIN 02503859 · $0.8197 PRZ-Sitagliptin · DIN 02545845 · $0.8197 Sandoz Sitagliptin · DIN 02504057 · $0.8197 Sitagliptin · DIN 02529041 · $0.8197 Sitagliptin · DIN 02548569 · $0.8197 Taro-Sitagliptin Fumarate · DIN 02531658 · $0.8197 Teva-Sitagliptin Malate · DIN 02522713 · $0.8197
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02428288
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Sitagliptin Malate · DIN 02508664 · 50mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Sitagliptin Malate · DIN 02508664 Manufacturer: Apotex Inc.; listing date 2022-12-21 Health Canada: Marketed since 2022-11-07 · brand APO-SITAGLIPTIN MALATE · ATC A10BH01 SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN MALATE) 50 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Sitagliptin Malate: Formulary list price $0.8197/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.8197 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99801 · Verify on the e-Formulary ↗ (DIN 02508664)

Source record
DIN 02508664: Apo-Sitagliptin Malate Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002047; group id 756; item number 1855; lccId None; manufacturer id APX Source form: Tab; strength: 50mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.8197; ministry $0.8197 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02508664 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99801 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Ach-Sitagliptin · DIN 02512483 · $0.8197 Apo-Sitagliptin · DIN 02428288 · $0.8197 Auro-Sitagliptin · DIN 02529874 · $0.8197 Jamp Sitagliptin · DIN 02534142 · $0.8197 Januvia · DIN 02388847 · $0.8197 M-Sitagliptin · DIN 02534991 · $0.8197 Mint-Sitagliptin · DIN 02553929 · $0.8197 NAT-Sitagliptin · DIN 02558165 · $0.8197 PMS-Sitagliptin · DIN 02503859 · $0.8197 PRZ-Sitagliptin · DIN 02545845 · $0.8197 Sandoz Sitagliptin · DIN 02504057 · $0.8197 Sitagliptin · DIN 02529041 · $0.8197 Sitagliptin · DIN 02548569 · $0.8197 Taro-Sitagliptin Fumarate · DIN 02531658 · $0.8197 Teva-Sitagliptin Malate · DIN 02522713 · $0.8197
Shortage status: active shortage (reported 2025-11-04, last updated 2026-01-29); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02508664
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Sitagliptin · DIN 02529874 · 50mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Sitagliptin · DIN 02529874 Manufacturer: Auro Pharma Inc.; listing date 2023-03-31 Health Canada: Marketed since 2023-01-05 · brand AURO-SITAGLIPTIN · ATC A10BH01 SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE) 50 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Sitagliptin: Formulary list price $0.8197/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.8197 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101910 · Verify on the e-Formulary ↗ (DIN 02529874)

Source record
DIN 02529874: Auro-Sitagliptin Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002047; group id 756; item number 1855; lccId None; manufacturer id AUR Source form: Tab; strength: 50mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.8197; ministry $0.8197 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02529874 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101910 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Ach-Sitagliptin · DIN 02512483 · $0.8197 Apo-Sitagliptin · DIN 02428288 · $0.8197 Apo-Sitagliptin Malate · DIN 02508664 · $0.8197 Jamp Sitagliptin · DIN 02534142 · $0.8197 Januvia · DIN 02388847 · $0.8197 M-Sitagliptin · DIN 02534991 · $0.8197 Mint-Sitagliptin · DIN 02553929 · $0.8197 NAT-Sitagliptin · DIN 02558165 · $0.8197 PMS-Sitagliptin · DIN 02503859 · $0.8197 PRZ-Sitagliptin · DIN 02545845 · $0.8197 Sandoz Sitagliptin · DIN 02504057 · $0.8197 Sitagliptin · DIN 02529041 · $0.8197 Sitagliptin · DIN 02548569 · $0.8197 Taro-Sitagliptin Fumarate · DIN 02531658 · $0.8197 Teva-Sitagliptin Malate · DIN 02522713 · $0.8197
Shortage status: resolved shortage (ended 2025-01-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02529874
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Sitagliptin · DIN 02534142 · 50mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Sitagliptin · DIN 02534142 Manufacturer: Jamp Pharma Corporation; listing date 2023-03-31 Health Canada: Marketed since 2023-02-02 · brand JAMP SITAGLIPTIN · ATC A10BH01 SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE) 50 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Sitagliptin: Formulary list price $0.8197/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.8197 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102309 · Verify on the e-Formulary ↗ (DIN 02534142)

Source record
DIN 02534142: Jamp Sitagliptin Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002047; group id 756; item number 1855; lccId None; manufacturer id JPC Source form: Tab; strength: 50mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.8197; ministry $0.8197 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02534142 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102309 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Ach-Sitagliptin · DIN 02512483 · $0.8197 Apo-Sitagliptin · DIN 02428288 · $0.8197 Apo-Sitagliptin Malate · DIN 02508664 · $0.8197 Auro-Sitagliptin · DIN 02529874 · $0.8197 Januvia · DIN 02388847 · $0.8197 M-Sitagliptin · DIN 02534991 · $0.8197 Mint-Sitagliptin · DIN 02553929 · $0.8197 NAT-Sitagliptin · DIN 02558165 · $0.8197 PMS-Sitagliptin · DIN 02503859 · $0.8197 PRZ-Sitagliptin · DIN 02545845 · $0.8197 Sandoz Sitagliptin · DIN 02504057 · $0.8197 Sitagliptin · DIN 02529041 · $0.8197 Sitagliptin · DIN 02548569 · $0.8197 Taro-Sitagliptin Fumarate · DIN 02531658 · $0.8197 Teva-Sitagliptin Malate · DIN 02522713 · $0.8197
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02534142
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Januvia · DIN 02388847 · 50mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Januvia · DIN 02388847 Manufacturer: Merck Frosst Canada Ltd.; listing date 2013-09-27 Health Canada: Marketed since 2012-09-17 · brand JANUVIA · ATC A10BH01 SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG · company Merck canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.8197 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87439 · Verify on the e-Formulary ↗ (DIN 02388847)

Source record
DIN 02388847: Januvia Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002047; group id 756; item number 1855; lccId None; manufacturer id MFC Source form: Tab; strength: 50mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $3.4098; ministry $0.8197 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02388847 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87439 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Ach-Sitagliptin · DIN 02512483 · $0.8197 Apo-Sitagliptin · DIN 02428288 · $0.8197 Apo-Sitagliptin Malate · DIN 02508664 · $0.8197 Auro-Sitagliptin · DIN 02529874 · $0.8197 Jamp Sitagliptin · DIN 02534142 · $0.8197 M-Sitagliptin · DIN 02534991 · $0.8197 Mint-Sitagliptin · DIN 02553929 · $0.8197 NAT-Sitagliptin · DIN 02558165 · $0.8197 PMS-Sitagliptin · DIN 02503859 · $0.8197 PRZ-Sitagliptin · DIN 02545845 · $0.8197 Sandoz Sitagliptin · DIN 02504057 · $0.8197 Sitagliptin · DIN 02529041 · $0.8197 Sitagliptin · DIN 02548569 · $0.8197 Taro-Sitagliptin Fumarate · DIN 02531658 · $0.8197 Teva-Sitagliptin Malate · DIN 02522713 · $0.8197
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02388847
Shortage record checked 2026-09-13T08:10:21.292534+00:00

M-Sitagliptin · DIN 02534991 · 50mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
M-Sitagliptin · DIN 02534991 Manufacturer: Mantra Pharma Inc.; listing date 2026-07-31 Health Canada: Marketed since 2026-05-11 · brand M-SITAGLIPTIN · ATC A10BH01 SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG · company Mantra pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

M-Sitagliptin: Formulary list price $0.8197/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.8197 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102388 · Verify on the e-Formulary ↗ (DIN 02534991)

Source record
DIN 02534991: M-Sitagliptin Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002047; group id 756; item number 1855; lccId None; manufacturer id MAT Source form: Tab; strength: 50mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.8197; ministry $0.8197 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02534991 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102388 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Ach-Sitagliptin · DIN 02512483 · $0.8197 Apo-Sitagliptin · DIN 02428288 · $0.8197 Apo-Sitagliptin Malate · DIN 02508664 · $0.8197 Auro-Sitagliptin · DIN 02529874 · $0.8197 Jamp Sitagliptin · DIN 02534142 · $0.8197 Januvia · DIN 02388847 · $0.8197 Mint-Sitagliptin · DIN 02553929 · $0.8197 NAT-Sitagliptin · DIN 02558165 · $0.8197 PMS-Sitagliptin · DIN 02503859 · $0.8197 PRZ-Sitagliptin · DIN 02545845 · $0.8197 Sandoz Sitagliptin · DIN 02504057 · $0.8197 Sitagliptin · DIN 02529041 · $0.8197 Sitagliptin · DIN 02548569 · $0.8197 Taro-Sitagliptin Fumarate · DIN 02531658 · $0.8197 Teva-Sitagliptin Malate · DIN 02522713 · $0.8197
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02534991
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mint-Sitagliptin · DIN 02553929 · 50mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mint-Sitagliptin · DIN 02553929 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2026-03-31 Health Canada: Marketed since 2025-12-10 · brand MINT-SITAGLIPTIN · ATC A10BH01 SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE) 50 MG · company Mint pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mint-Sitagliptin: Formulary list price $0.8197/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.8197 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104282 · Verify on the e-Formulary ↗ (DIN 02553929)

Source record
DIN 02553929: Mint-Sitagliptin Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002047; group id 756; item number 1855; lccId None; manufacturer id MIN Source form: Tab; strength: 50mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.8197; ministry $0.8197 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02553929 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104282 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Ach-Sitagliptin · DIN 02512483 · $0.8197 Apo-Sitagliptin · DIN 02428288 · $0.8197 Apo-Sitagliptin Malate · DIN 02508664 · $0.8197 Auro-Sitagliptin · DIN 02529874 · $0.8197 Jamp Sitagliptin · DIN 02534142 · $0.8197 Januvia · DIN 02388847 · $0.8197 M-Sitagliptin · DIN 02534991 · $0.8197 NAT-Sitagliptin · DIN 02558165 · $0.8197 PMS-Sitagliptin · DIN 02503859 · $0.8197 PRZ-Sitagliptin · DIN 02545845 · $0.8197 Sandoz Sitagliptin · DIN 02504057 · $0.8197 Sitagliptin · DIN 02529041 · $0.8197 Sitagliptin · DIN 02548569 · $0.8197 Taro-Sitagliptin Fumarate · DIN 02531658 · $0.8197 Teva-Sitagliptin Malate · DIN 02522713 · $0.8197
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02553929
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (68:20:02 Oral Anti-Diabetic Agents) and how they are covered

Matched class: 68:20:02 Oral Anti-Diabetic Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CANAGLIFLOZIN, DAPAGLIFLOZIN, DAPAGLIFLOZIN & METFORMIN, EMPAGLIFLOZIN, EMPAGLIFLOZIN & METFORMIN, LINAGLIPTIN, LINAGLIPTIN & METFORMIN, SAXAGLIPTIN, SAXAGLIPTIN & METFORMIN Some products covered without a code (check the product listing): GLICLAZIDE, GLYBURIDE, METFORMIN HCL 68:20:02 Oral Anti-Diabetic Agents

LINAGLIPTIN

· 1 products · General benefit · strengths: 5mg · Tab

SAXAGLIPTIN

· 6 products · General benefit · strengths: 2.5mg, 5mg · Tab

CANAGLIFLOZIN

· 8 products · General benefit · strengths: 100mg, 300mg · Tab

DAPAGLIFLOZIN

· 22 products · General benefit · strengths: 5mg, 10mg · Tab

DAPAGLIFLOZIN & METFORMIN

· 6 products · General benefit · strengths: 5mg & 1000mg, 5mg & 850mg · Tab

EMPAGLIFLOZIN

· 2 products · General benefit · strengths: 10mg, 25mg · Tab

EMPAGLIFLOZIN & METFORMIN

· 6 products · General benefit · strengths: 5mg & 1000mg, 5mg & 500mg, 5mg & 850mg, 12.5mg & 1000mg, 12.5mg & 500mg, 12.5mg & 850mg · Tab

GLICLAZIDE

· 19 products · General benefit (18), Listed, not a benefit (1) · strengths: 60mg, 30mg, 80mg · ER Tab, SR Tab, Tab

GLYBURIDE

· 8 products · General benefit (6), Listed, not a benefit (2) · strengths: 2.5mg, 5mg · Tab

LINAGLIPTIN & METFORMIN

· 3 products · General benefit · strengths: 2.5mg & 1000mg, 2.5mg & 500mg, 2.5mg & 850mg · Tab

METFORMIN HCL

· 53 products · Off-Formulary Interchangeable, not an ODB benefit (33), General benefit (19), Off-Formulary Interchangeable, not an ODB benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1) · strengths: 500mg, 1000mg, 850mg · ER Tab, Tab

SAXAGLIPTIN & METFORMIN

· 3 products · General benefit · strengths: 2.5mg & 1000mg, 2.5mg & 500mg, 2.5mg & 850mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:20:02 and 5 more
Full class listing Related classes: 68:20:06 Incretin Mimetics, 68:20:10 Insulins (Rapid Acting), 68:20:12 Insulins (Intermediate Acting), 68:20:14 Insulins (Long Acting), 68:20:16 Insulins (Pre-Mixed) Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS • Monotherapy: JANUVIA® (sitagliptin) is indicated for use as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus for whom metformin is inappropriate due to contraindications or intolerance. • Add-on combination: JANUVIA® is indicated in adult patients with type 2 diabetes mellitus to improve glycemic control, in combination with: . metformin, . metformin and a sulfonylurea, . pioglitazone (alone or with metformin), . premixed or long/intermediate acting insulin (alone or with metformin) when the existing therapy, along with diet and exercise, does not provide adequate glycemic control (see 14 CLINICAL TRIALS). 1.1 Pediatrics • Pediatrics (<18 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of JANUVIA®in pediatric patients has not been established; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics • Geriatrics (≥65 years of age): Based on the data submitte… https://pdf.hres.ca/dpd_pm/00074500.PDF PM date: FEB 07, 2024 Source product: JANUVIA; DIN 02303922; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS • JANUMET® (sitagliptin/metformin hydrochloride) and JANUMET® XR (sitagliptin/metformin hydrochloride extended-release) are indicated for use as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus inadequately controlled on metformin or in patients already being treated with the combination of sitagliptin and metformin. • Add-on combination: JANUMET® and JANUMET® XR are indicated for use as a triple combination therapy in adult patients with type 2 diabetes mellitus to improve glycemic control, in combination with: o . sulfonylurea, o . premixed or long/intermediate acting insulin o . pioglitazone when the existing dual therapy with metformin, along with diet and exercise, does not provide adequate glycemic control (see 14 CLINICAL TRIALS). 1.1 Pediatrics • Pediatrics (<18 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of JANUMET® and JANUMET® XR in pediatric patients… https://pdf.hres.ca/dpd_pm/00074655.PDF PM date: FEB 20, 2024 Source product: JANUMET; DIN 02333856; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Ach-Sitagliptin · DIN 02512475 Shortage status: active shortage (reported 2024-06-28, last updated 2024-08-09) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02512475

Check this DIN again

Apo-Sitagliptin Malate · DIN 02508656 Shortage status: active shortage (reported 2025-10-14, last updated 2026-01-29); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02508656

Check this DIN again

Taro-Sitagliptin Fumarate · DIN 02531631 Shortage status: active shortage (reported 2026-06-01, estimated to end 2026-10-02, last updated 2026-09-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02531631

Check this DIN again

Teva-Sitagliptin Malate · DIN 02522705 Shortage status: active shortage (reported 2025-03-05, last updated 2025-12-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02522705

Check this DIN again

Ach-Sitagliptin · DIN 02512483 Shortage status: active shortage (reported 2024-06-28, last updated 2024-08-09) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02512483

Check this DIN again

Apo-Sitagliptin Malate · DIN 02508664 Shortage status: active shortage (reported 2025-11-04, last updated 2026-01-29); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02508664

Check this DIN again